Bristol Myers Squibb Patent-Cliff Exposure & CMS Drug Spending Portfolio

Bristol Myers Squibb (Princeton, NJ): 36 reconciled FDA prescription therapies (85.1% 2025 to 2030 cliff risk), $32.18B 2024 CMS Part D & Medicaid spend, and 101 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterPrinceton, NJ
Reconciled FDA Portfolio Therapies36
2025 to 2030 Patent-Cliff Revenue Exposure85.1%
Primary Portfolio LOE Date2026-01-01
2024 CMS Total Public Spend$32.18B
2024 Medicare Part D Spend$29.44B
2024 Medicaid Spend$2.74B
California HCAI SB 17 Filings101 WAC filings (max 29.5% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Bristol Myers Squibb across sibling Meru public-data platforms.